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Several 6-aryl-4-substituted benzylidene/furfurylidene pyridazin(2H)-3-one derivatives (4a-f) were 
synthesized and evaluated as analgesic and anti-inflammatory agents in mice and rats, respectively. 
All compounds were tested by using Eddy’s hot plate and the carrageenan-induced hind paw oedema 
method for the evaluation of analgesic and anti-inflammatory activities, respectively. Results showed 
that compounds 4f, 4b, 4d, and 4e exhibited higher analgesic and anti-inflammatory activities than other 
remaining compounds. All title compounds (4a-f) were characterized by IR, NMR and Mass spectroscopy.
Uniterms: Pyridazinone/evaluation/experimental study. Analgesics/evaluation/experimental study. Anti-
inflammatories/evaluation/experimental study.. Synthetic compounds/evaluation/experimental study..
Diversos derivados benzilideno/furfurilideno piridazin(2H)-3-ona 6-aril-4-substituídos (4a-f) foram 
sintetizados e avaliados como analgésicos e anti-inflamatórios em camundongos e ratos, respectivamente. 
Todos os compostos foram testados utilizando-se o método de placa quente de Eddy e o de edema de pata 
induzido por carragenana para a avaliação das atividades analgésica e anti-inflamatória, respectivamente. 
Os resultados mostraram que os compostos 4f, 4b, 4d e 4e exibiram atividade analgésica e anti-inflamatória 
mais alta do que os compostos restantes. Todos os compostos (4a-f) foram caracterizados por IV, RMN 
e espectrometria de massas. 
Unitermos: Piridazinona/avaliação/estudo experimental. Analgésicos/avaliação/estudo experimental. 
Anti-inflamatórios/avaliação/estudo experimental. Compostos sintéticos/avaliação/estudo experimental.
INTRODUCTION
The classical non-steroidal anti-inflammatory drugs 
(NSAIDs) are useful for the treatment of inflammation, 
pain and fever. The actions of NSAIDs are based on the 
inhibition of the enzyme cyclooxygenase (COX), which 
catalyzes the metabolism arachidonic acid (AA) to 
prostaglandin H2 (PGH2). PGH2 is further metabolized to 
prostanoids, prostaglandins (PGs) and thromboxane-A2 
(TXA2). Various physiological effects of PGs include 
acute and chronic inflammatory reactions, blood pressure 
(BP) change, platelet aggregation, induction of labor and 
intensification of pain and fever. However, long-term 
usage of NSAIDs is associated with several side effects 
including gastrointestinal (GI) lesions, bleeding, as well as 
hepato- and nephro-toxicities (Hallas et al., 1995; Mccarthy, 
1998; Raskin, 1999). In designing new drug molecules, 
developing safer analgesic and anti-inflammatory drugs 
without such side effects has recently been the goal of many 
researchers. Different pharmacophores with a different 
mode of action in the structure may lead to compounds 
having efficiency in biological activity.
Research has been directed in recent years, where 
a substantial number of 6-aryl-pyridazin-3(2H)ones 
have been reported to possess various types of biological 
activities such as antimicrobial, antifeedant, herbicidal, 
antihypertensive, antipyretic, antiplatelet, anticancer, 
anticonvulsant, antitubercular, cardiotonic and other 
anticipated activities (Jing et al., 2007; Islam et al., 2008). 
On the other hand, a considerable number of pyridazine-
3(2H)one derivatives are endowed with analgesic and anti-
inflammatory properties (Siddiqui et al., 2004; Dogruer, 
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et al., 2007). Among the various pyridazine compounds, 
3-amino-6-methyl-pyridazine-4-thiol (ES-1007) (1) is 
marketed in Germany (Pyridazine analogue) and 4-ethoxy-
2-methyl-5-morpholino-3(2H)-pyridazinone (emorfazone) 
(1) is being marketed as pentoil and nandron in Japan as an 
analgesic and anti-inflammatory drug (Rubat, et al., 1992, 
Pinna et al., 1992; Flouzat et al., 1993).
 
Diverse pharmacological activities of the compounds 
containing pyridazinone moieties (Dogruer, et al., 2003; 
Şukuroglu, et al., 2006; Baytas, et al., 2012) have 
prompted us to synthesize new compounds with analgesic 
and anti-inflammatory activities that may be potent, 
selective and less toxic.
Stimulated by these findings, our attention has 
been focused on the synthesis and evaluation of some 
6-nitrophenylpyridazin-3(2H)-one derivatives (4a-f) 
as analgesic and antiinflammatory agents using the hot 
plate model and carrageenan-induced oedema model, 
respectively. Aspirin and indomethacin were used as 
reference drugs for analgesic and antiinflammatory 
activities, respectively. All title compounds (4a-f) have 
nitrophenyl at position 6 and a benzylidene/furfurylidine 
ring at position 4 on the pyridazinone ring. The results 
of the biological screening indicated that all compounds 
(4a-f) possess significant anti-inflammatory and analgesic 
activities.
MATERIAL AND METHODS
All the title compounds 6-(3’-nitrophenyl)-4-
benzylidene-2,3,5-trihydro-pyridazin-3-one (4a-f) were 
synthesized by condensation of 6-(3’-nitrophenyl)-4,5-
dihydro pyridazin-3(2H)-one (3) with different aromatic 
aldehydes (benzaldehyde, 4-hydroxy-3-methoxy 
benzaldehyde, 4-hydroxybenzaldehyde, 2-methoxy 
benzaldehyde, venilline and furfuraldehyde). Compound 
(3) was synthesized by cyclization of β-m-nitro benzoyl 
propionic acid (2) with hydrazine hydrate. A compound 
(2) was prepared by nitration of benzoyl propionic acid 
(1) by nitrating mixture (conc. HNO3 and conc. H2SO4). 
Compound (1) was prepared by Friedal craft reaction 
of benzene with succinic anhydride in the presence of 
anhydrous aluminium chloride. All the compounds (4a-f) 
were previously synthesized by the same author and 
evaluated as anticonvulsants (Siddiqui et al., 2007; Asif, 
et al., 2011).
Characterization and spectral analysis of 
synthesized compounds
b-Benzoyl propionic acid (1)
Melting point: 120 oC, yield 70% Rf value 0.77, 
molecular formula C10H10O3, molecular weight 178.18. 
Elemental analysis: (found/ calculated) H: 5.65/5.73 and 
C: 67.40/67.88. IR Spectra: 3250 cm-1 (OH),1720 cm-1 
(C=O), 1HNMR(CDCl3) ppm 2.82 (2H, t, CH2), 3.32 (2H, 
t, CH2), 7.74 (CH2, m, H-3, 5), 7.79 (2H, m, H-2, 6), MS 
(m/z): 174 (M+1).
b-m-nitro benzoyl propionic acid (2)
Melting point: 108 oC, yield 50 %, Rf value 0.70, 
molecular formula C10H9NO5, molecular weight 223.18. 
Elemental analysis: (found/ calculated), H: 4.06/4.054, 
C: 53.81/53.62 and N: 6.27/6.87. IR Spectra: 3091 cm-1 
FIGURE 1 - Structure of pyridazinone compound ES-1007 and 
emorfazone.
FIGURE 2 - Synthetic route for pyridazinone derivatives.
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·	6-(3’-nitrophenyl)–4-(2-methoxy)benzylidene-2,3,5-
-trihydro-pyridazin-3-one (4d)
Melting point: 146 oC, yield 50%, molecular 
formula C18H12O4N3, molecular weight 334.311. Elemental 
analysis: (found/calculated), H: 3.61/3.73, C: 64.66/64.49 
and N: 12.56/12.59. IR cm-1 -1685 cm-1 (C=O), 1352 
cm-1 (NO2), 3450 cm-1 (NH), 1580 cm-1 (C=C), 1300 cm-1 
(C=O). 1HNMR (CDCl3) ppm: 2.2 (s, 2H, CH2), 4.07 (s, 
H, OCH3), 7.5 (s, H, NH), 7.4 – 8.2 (m, H, Ar-H), 4.0 (s, 
H, NH), MS (m/z): 337 (M+).
·	6-(3’-nitrophenyl)-4-(4-N,N-dimethyl-amino)benzyli-
dene-2,3,5-trihydro-pyridazin-3-one (4e)
Melting point: 158 oC, yield 60%, molecular 
formula C19H18O3N4, molecular weight 350.37. Elemental 
analysis: (found/calculated), H: 5.17/5.43, C: 65.13/65.23 
and N:15.99/15.65. IR cm-1 -1685 cm-1 (C=O), 1352 
cm-1 (NO2), 3450 cm-1 (NH), 1580 cm-1 (C=C). 1HNMR 
(CDCl3) ppm 3.9 (s, 3H, CH3), 3.1 (s, 3H, CH3), 2.0 (s, 2H, 
CH2), 7.2 (s, H, NH), 6.7 (d, H, Ar-H), 7.7 (t, H, Ar-H), 
8.6 (s, H, Ar-H), 8.8 (d, H, Ar-H), MS (m/z): 351 (M+1).
·	 6-(3’-nitrophenyl)-4-(furfurylidene)-2,3,5-trihydro-
-pyridazin-3-one (4f)
Melting point: 157 oC, yield 65%, molecular formula 
C15H11O4N3, molecular weight 297.27. Elemental analysis: 
(found/calculated), H: 3.72/3.79, C: 60.60/60.68 and N: 
14.13/14.53.IR cm-1 -1650 cm-1 (C=O), 1352cm-1 (NO2), 
3440 cm-1 (NH). 1HNMR (DMSO) ppm 2.5 (s, 2H, CH2), 
6.5 (m, H, fur-H), 6.9 (d, H, fur-H), 7.7 (t, H, fur-H), 7.5 
(s, H, NH), 7.6 (m, H, nitro Ar-H), 8.4 – 8.8 (m, H, nitro 
Ar-H), MS (m/z): 298 (M+1).
Preparation of test samples for bioassay
All test samples (50 mg/kg) were suspended in a 
mixture of distilled water and 0.5% sodium carboxyl 
methylcellulose (CMC) and were given intraperitoneally 
(i.p.) to the test animals. The animals of the control group 
received the same experimental handling except that 
the test drug treatment was replaced with appropriate 
volumes of the vehicle. Indomethacin (10 mg/kg) for anti-
inflammatory and aspirin at 0.5% CMC (50 mg/kg) for 
analgesic activity were used as reference drugs.
Experimental animals
Male Swiss albino rats (150-200 g) were used for 
anti-inflammatory activity and mice (30- 35 g) were used 
for analgesic activity. All of the animals were left for 2 
days in the laboratory for acclimatization before the day 
(CH), 1705 cm-1 (C=O), 1353 cm-1 (NO2), 1617 cm-1 
(C=C). 1HNMR (DMSO) ppm 3.0 (t, 2H, CH2), 3.36 (t, 
2H, CH2), 7.30- 8.2 (m, Ar-H), 8.82 (s, H, Ar-H), MS 
(m/z): 224 (M+1).
6-(3’-nitrophenyl)-4,5-dihydro pyridazin-3-one (3)
Yield 52%, melting point: 95 oC, Rf value 0.62, 
molecular formula C10H9NO5, molecular weight 193.2. 
Elemental analysis: (found/calculated), H: 5.73/5.32, 
C: 62.16/62.87, N:7.24/7.47. IR (cm-1)1685(C=O), 
1352(NO2), 3100(CH), 3550(NH), 1H NMR (CDCl3) 
(ppm): 2.45 (t, 2H, CH2-C-C6H5), 2.93 (t, 2H, CH2-
CONH), 7.41(m, 3H, Ar-H3’, Ar-H-5’), 7.74 (d, 2H, Ar-
H2’, Ar-H-6’), 10.94 (s, 1H, CONH), MS (m/z): 219 (M+).
6-(3’-nitrophenyl)-4-benzylidene-2,3,5-trihydro-
pyridazin-3-one (4a-f)
·	6-(3’-nitrophenyl)-4-benzylidene-2,3,5 trihydro-pyri-
dazin-3-one (4a)
Melting point: 132 oC, yield 65%, molecular 
formula C17H13O3N3, molecular weight 307.309 Elemental 
analysis: (found/calculated), H: 4.26/4.63, C: 66.44/66.20 
and N: 13.67/13.32. IR cm-1 -1360 cm-1 (NO2), 1700cm-1 
(C=O), 1580cm-1 (C=C) exo, 3450cm-1 (NH). 1HNMR 
(CDCl3) ppm 2.3 (s, 2H, CH2), 7.47-7.88 (m, H, Ar-H), 
8.5 (d, H, Ar-H), 8.3 (d, H, Ar-H), 7.0 (s, H, NH), 8.9 (s, 
H, Ar-H), MS (m/z): 307 (M+).
·	6-(3’-nitrophenyl)-4-(4-hydroxy-3-methoxy)benzyli-
dene-2,3,5-trihydropyridazin-3-one (4b)
Melting point: 127 oC, yield 50%, molecular 
formula C17H13O4N3, molecular weight 323.308. Elemental 
analysis: (found/calculated), H: 4.05/4.025, C: 
63.15/63.56 and N: 2.99/12.66. IR- cm-1 1700 cm-1 (C=C), 
1350 cm-1 (NO2), 3450 cm-1 (C=C), 1580 cm-1 (C=C) 
exo, 1310 cm-1 (C-O).1HNMR (CDCl3) ppm 7.4-7.8 (m, 
H, nitro Ar-H), 7.0 (s, H, NH), 7.6 (s, H, Ar-H), 7.4 (d, 
H, Ar-H), 7.7 (m, H, Ar-H), 3.8 (s, 3H,OCH3), 6.9 (s, 
H, Ar-H), 7.26 (s, H, CH), 4.08 (s, H, OH), MS (m/z): 
353 (M+).
·	6-(3’-nitrophenyl)-4-(4-hydroxy)benzylidene-2,3,5-
-trihydro-pyridazin-3-one (4c)
Melting point: 139 oC, yield 55%, molecular 
formula C17H13O4N3, molecular weight 323.308. Elemental 
analysis: (found/calculated), H: 4.05/4.031, C: 63.15/63.42 
and N: 12.99/12.46.IR cm-1 -1685 cm-1 (C=O), 1350 cm-1 
(NO2), 3450 cm-1 (NH), 3600 cm-1 (OH), 1580 cm-1 (C=C). 
1HNMR (DMSO) ppm: 2.0 (s, H, CH), 4.0 (s, H, OH), 7.3 
(s, H, CH), 6.9 (d, H, Ar-H), 7.78 (t, H, Ar-H), 6.8 (s, H, 
NH), 7.7 (s, H, Ar-H), MS (m/z): 323 (M+).
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of experiment, and on the last day they were given water 
only. A minimum of 5 animals were used in each group. 
All pharmacological activities were carried out as per 
CPCSEA (Committee for the Purpose of Control and 
Supervision of Experiments on Animals) norms (Regn No: 
1145/a/07/CPCSEA), after obtaining the approval from the 
Institutional Animal Ethics Committee of the Department 
of Pharmacy, GRD (PG) Institute of Management & 
Technology, Dehradun, India.
Analgesic activity
Eddy’s hot plate method
Heat was used as the source of pain. Animals were 
individually placed on the hot plate, maintained at a 
constant temperature (55 oC), and the reaction of animals, 
such as paw licking or jump response was taken as the end 
response. Analgesic compounds increased the reaction 
time. This method was described by Eddy & Leimbach 
(A cut-off period of 15 sec is observed to avoid damage to 
the paw). The control, standard and test compounds were 
administered to animals by the i.p route and the reaction 
of time of animals on the hot plate was noted at 10, 20, 
30, 40 & 50 min interval after drug administration by 
using a Techno heated plate analgesic apparatus. A group 
of albino mice were treated i.p. with a dose of 50 mg/kg 
body weight. The standard drug Aspirin (50 mg/kg) was 
used as the reference drug (Kulkarni, 1999). The results 
are tabulated in Table II.
Anti-inflammatory activity
Carrageenan-induced hind paw oedema test
For the determination of anti-inflammatory effect, 
the carrageenan-induced paw oedema model (Winter 
et al., 1962) was employed. Sixty minutes after the i.p 
administration of control, test samples and reference drug, 
each rat was injected with a freshly prepared 0.1 mL of 
1% carrageenan suspension in physiological saline (0.9% 
NaCl) into subplantar tissue of the right hind paw. For the 
control, 10 mL/kg saline solution was administered. Paw 
oedema was measured every 90 min for 6h after induction 
of inflammation. Mean values of the treated groups were 
compared with those of the control group and analyzed 
using statistical methods (Table III, IV).
Acute toxicity
All animals used in the analgesic and inflammatory 
experiments were observed for 48 h and mortality of 
animals recorded where present for each group at the end 
of observation period.
TABLE I - Structures of 6-(3’-nitrophenyl)-4-benzylidene-2,3,5-trihydro-pyridazin-3-one (4a-f)
SNo. Compounds R
1 6-(3’-nitrophenyl)-4-benzylidene-2,3,5 trihydro-pyridazin-3-one (4a) 
2 6-(3’-nitrophenyl)-4-(4-hydroxy-3-methoxy)benzylidene-2,3,5-trihydro-pyridazin-3-one (4b)
3 6-(3’-nitrophenyl)-4-(4-hydroxy)benzylidene-2,3,5-trihydro-pyridazin-3-one (4c)
4 6-(3’-nitrophenyl)–4-(2-methoxy)benzylidene-2,3,5-trihydro-pyridazin-3-one (4d)
5 6-(3’-nitrophenyl)-4-(4-N,N-dimethyl-amino)benzylidene-2,3,5-trihydro-pyridazin-3-one (4e)
6 6-(3’-nitrophenyl)-4-(furfurylidene)2,3,5-trihydro-pyridazin-3-one (4f)
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TABLE II - Analgesic activity of the synthesized compounds
Compd. No.
Time (min)
10 20 30 60 90 120
Control 3.42±0.03 3.48±0.02 3.64±0.04 3.50±0.03 3.76±0.04 3.64±0.05
4a 4.53 ± 0.02 5.73 ± 0.01 6.68 ± 0.02 9.42 ± 0.01 11.50 ± 0.01 12.12 ± 0.01
4b 4.34 ±0.01 5.72± 0.01 7.00± 0.01 9.68 ± 0.01 10.16± 0.01 11.53 ±0.01
4c 3.76± 0.01 4.45±0.01 5.86± 0.01 7.54± 0.01 9.96± 0.01 10.41± 0.01
4d 3.84± 0.01 4.68±0.01 5.94 ± 0.01 6.79± 0.01 8.92 ± 0.01 9.62 ± 0.01
4e 6.33± 0.02 7.63±0.02 8.44± 0.02 9.68 ±0.02 10.84 ± 0.01 12.14 ±0.01
4F 7.54± 0.01 9.65± 0.01 10.36±0.01 11.04± 0.01 12.01± 0.01 12.53± 0.02
Aspirin 8.54 ±0.01 10.58± 0.01 11.47±0.01 11.71 ± 0.01 12.73± 0.01 12.98± 0.01
All results are significantly different from control at a p < 0.001.
TABLE IV – Percentage inhibition of carrageenan-induced paw oedema (4a-f)
Compound. No.
Inhibition of oedema %
90 min 180 min 270 min 360 min
4a 14.63 18.00 22.80 28.71
4b 29.27 36.00 36.84 36.92
4c 17.07 26.00 30.00 35.38
4d 24.39 32.00 35.08 36.92
4e 14.63 22.00 26.31 32.30
4F 29.27 36.00 38.59 40.00
Indomethacin 34.14 37.00 42.35 44.53
All results are significantly different from control at a p < 0.001.
TABLE III - Anti-inflammatory Activities of the Compounds
Compounds
Anti-inflammatory Activity
Change in mean paw volume (ml) ± SEM
90 min 180 min 270 min 360 min
Control 0.41 ± 0.03 0.50 ± 0.01 0.57 ± 0.03 0. 65 ± 0.04
4a 0.35 ± 0.02 0.41 ± 0.04 0.44 ± 0.04 0.49 ± 0.04
4b 0.29 ± 0.03 0.32 ± 0.03 0.36 ± 0.03 0.41 ± 0.03
4c 0.34 ± 0.01 0.37 ± 0.02 0.39 ± 0.03 0.42 ± 0.03
4d 0.31 ±0.03 0.34 ±0.02 0.37 ± 0.01 0.41 ± 0.01
4e 0.35 ± 0.05 0.39 ± 0.009 0.42 ± 0.03 0.44 ± 0.03
4f 0.29 ±0.03 0.32 ± 0.01 0.35 ± 0.02 0.39 ± 0.02
Indomethacin 0.26 ± 0.008 0.30 ± 0.03 0.32 ± 0.02 0.36 ± 0.02
All results are significantly different from control at a p < 0.001.
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Statistical analysis
Results were expressed as means ± s.e.m. Statistical 
significance was analyzed by using the one-way analysis 
of variance followed by Tukey’s Multiple Comparison Test 
where p < 0.05 was accepted to be a significant difference.
RESULTS AND DISCUSSION
All the 6-(3’-nitrophenyl)-2,3,5-trihydro pyridazin-
3-one derivatives (4a-f) exhibited analgesic activities 
(Table I) that lasted for 120 minutes with potency that 
increased with time. All compounds were less potent than 
the reference drug Aspirin, but the most potent compounds 
were (4e and 4f) and least potent compound was 4d . 
Thus, the degree of potency in ascending order was 4d, 
4c, 4b 4a, 4e, and 4f. All the tested compounds showed 
anti-inflammatory activity (Table III). Compounds 4b, 4f 
and 4d showed high protection against induced oedema 
after 360 min. whereas compounds 4a, 4c, 4e showed 
less potency. The degree of anti-inflammatory potency 
in ascending order was: 4a, 4e, 4c, 4d, 4b, and 4f by % 
Inhibition of carrageenan-induced paw oedema (Table 
IV). Substitution on the pyridazinone ring at position 
4 by furfurylidine was considered to have greater anti-
inflammatory and analgesic activity. For acute toxicity, no 
animals died during a 48-hr. period of observation after 
experiments.
The discovery of novel, potent and safer non-
steroidal anti-inflammatory drugs (NSAIDs) represents a 
challenging goal (Van, Botting, 1995) because resistance 
to NSAIDs is widespread. Therefore, there is an increasing 
need for identification of lead structures that may be of 
use in designing new, potent drugs with less toxic effects 
(Takaya et al., 1979; Heinisch et al., 1990). In addition, 
some pyridazinone derivatives have been found to exhibit 
potent NSAIDs activity through the selective COX-2 
inhibitory mechanism (Chintakunta et al., 2002) and some 
pyridazinone compounds were also found to be more 
potent than reference drugs.
Further investigations in the future should determine 
analgesic and anti-inflammatory potency for title 
compounds, the effect of specific substituents and their 
positions in the molecules, and their related toxicity. In 
fact, the presence of a nitro-aryl moiety in all analogs 
raises a concern regarding liver toxicity; due to the action 
of NADPH-cytochrome P450 reductases, and will also be 
studied. In addition, we shall study the compound without 
a nitro group and study the impact of the nitro group on 
aryl moiety for analgesic and anti-inflammatory potency. 
Other substituted arylidines, with or without hetero 
atoms, will be tested in order to confirm the most active 
compounds of this group.
CONCLUSION
In conclusion, we reported here several pyridazinone 
compounds as analgesic and anti-inflammatory agents. 
Initial results demonstrated that the pyridazine ring 
may contribute to their analgesic and anti-inflammatory 
activities. These nitrophenyl pyridazinones have an 
m-nitrophenyl ring at position 6 and benzylidine/
furfurylidine at position 4. On the basis of these results, 
furfurylidine derivatives seem to be more potent for both 
analgesic and anti-inflammatory activities than other 
substituted benzylidine derivatives.
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